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Purpose: Current cancer treatment options include surgical intervention, radiotherapy and chemotherapy. The quality 
of the provision of each of them and their effective coordination determines the results in terms of benefit/risk. 
Regarding the radiation oncology treatments, there are not stabilised quality indicators to be used to perform control 
and continuous improvement processes for healthcare services. Therefore, the Spanish Society of Radiation Oncology 
has undertaken a comprehensive project to establish quality indicators for use with the information systems available 
in most Spanish healthcare services. Methods: A two-round Delphi study, examining consensus of several possible 
quality indicators (n=28) in daily practice. These indicators were defined after a bibliographic search and the 
assessment by radiation oncology specialists (n=8). They included aspects regarding treatment equipment, patient 
preparation, treatment and follow-up processes and were divided in structure, process and outcome indicators. 
Results: After the evaluation of the defined quality indicators (n=28) by an expert panel (38 radiation oncologist); 26 
indicators achieved consensus in terms of agreement with the statement. Two quality indicators did not achieve 
consensus. Conclusions: There is a high degree of consensus in Spanish Radiation Oncology specialists on which 
indicators in routine clinical practice can best measure quality. These indicators can be used to classify services based 
on several parameters (patients, equipments, complexity of the techniques used and scientific research). Furthermore, 










The Institute of Medicine [1] reported (2001) 1% of deaths every year caused by medical errors in Unites States (US). 
Many reasons could promote this situation; the most frequent are: treatment delays, dose errors, treatment delivery 
errors, unsuitable treatments or errors in treatment equipment. 
The three synergistic pillars of the current cancer treatment are surgery, radiotherapy and chemotherapy. The quality 
of the provision of each of them and their effective coordination determine to outcomes.  
Radiation oncology (RO) quality assurance in Spain is regulated by law [2]; however, this law does not establish the 
definition of any type of quality indicators to be used to perform control and continuous improvement processes for 
healthcare services. This study focuses on: RO treatments, the instrumental quality control (including treatment 
equipment and patient preparation), treatment and follow-up processes.  
In cancer patients, the National Cancer Institute [3] defines quality of care as “the provision of evidence-based, patient-
centered services throughout the continuum of care in a timely and technically competent manner, with good 
communication, shared decision making, and cultural sensitivity, with the aim of improving clinical outcomes, 
including patient survival and health-related quality of life (QoL)”.   
The complexity of the quality of cancer care is impossible to measure without suitably comprehensive indicators to 
assess the various components of quality and which are sensitive to progressive and regressive changes in daily 
practice.  
The Spanish Society of RO (SEOR), concerned with ensuring the best possible care to each patient, has undertaken a 
comprehensive project for the continuous quality improvement in Spanish RO. The aim of this project is to select, 
prioritize and define some indicators of use suitability and quality of healthcare for SEOR. The first part of this project 
was realized by an expert Working Group (WG) that selected the quality indicators that SEOR proposes as appropriate 
for use with the information systems available in most Spanish healthcare services. On this basis, the project will 
continue to promote quality measurements in these services and to establish individual/collective improvement 
objectives. The study was completed establishing detailed standards of good practice for each indicator selected (and 
additional information to facilitate their correct use and widespread implementation) in collaboration with Spanish 




Collaborative project for professional consensus promoted by SEOR, involving RO specialists assisted by SECA 
specialists and a university technical-team specialized in qualitative research techniques and group dynamics. The 
process was carried out in 4 consecutive phases, each with different aims and participants, between February and 
December 2015.  
Phase 1: Literature review of the study subject matter by a search in biomedical databases (Medline, Excerpta 
Médica, CancerLIT, National Guideline Clearinghouse, Cochrane Library Plus, Guía Salud, Lilacs, IME). The 
objective was to identify previous proposals, at national or international level, regarding criteria, indicators and 
healthcare quality standards in RO; either in general or linked to specific pathologies.  
The extensive collection of publications founded (n=38), with information on appropriate use and healthcare quality 
in RO (original articles, systematic reviews, expert consensus, clinical guidelines, healthcare technology evaluation 
reports, and other technical documents), was analyzed and evaluated by an WG. This WG was composed of eight RO 
specialists, with interest and/or training in healthcare quality. They analyzed the quality of the documents, identifying 
possible quality indicators and choosing and transcribing those considered appropriate for Spanish RO for discussion 
among professionals in the subsequent phases of the project.  
Subsequently, based on the expert input (who suggested between 10 and 28 items) to avoid concept repetition or 
overlap; the specialized members of the technical team produced a common documentary base of 48 possible clearly-
defined indicators (Table 1). According to the classification proposed by Donabedian [4], this initial set was composed 
of 7 structure indicators, 24 process indicators and 17 outcome indicators (including the treated patients opinion). 
Phase 2. Pre-selection of indicators subject to professional consensus. The WG set the international aim of not 
exceeding 25 indicators, completely covering the patient preparation, the treatment and the follow-up process in RO 
services. The aim was to ensure the manageability of the final proposal indicators in the improvement plans of the 
specific healthcare units and the viability of measuring them under real standard practice 
Each group member assessed the relevance of each of the 48 indicators proposed (secret vote), using a scale of 0-10 
(lowest-highest relevance), considering the 0-4 range score as a "non-critical indicator", and the 5-10 range as an 
"essential indicator". The group was then informed of the average score for each indicator after their initial positioning. 
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After free discussion, a second round of secret vote was performed to confirm the final selection of the items with the 
greatest support. In this round, each member could accept a maximum of 20 indicators; the rest would be rejected. 
Eventually, 28 indicators with the most support were chosen (8 structure, 15 process and 5 outcome indicators) (Table 
1). 
Phase 3. Validation of the final selection of the indicators chosen by structured professional consensus. A two-
rounds Delphi technique was carried out to involve an external representative of the WG in the final approval process 
of the definitive indicators that SEOR would like to disseminate as its own. 
A Panel of Experts was constituted with 38 of the 51 expert radiation oncologists invited, using a snowball or chain 
sampling strategy among SEOR associates. All members, with broad geographical representativeness (nationwide), 
had recognised professional prestige in the field of study,  
Given the experts' expected systematic support for all items (practically all of which are from prestigious scientific 
documentary sources), the objective was: to endorse the suitability of each indicator and to determine the priority 
among the indicators according to the need to be implemented in the evaluation processes regarding healthcare quality 
in the specialty. 
The Delphi method is a distance professional consensus technique using written surveys broadly used in biomedical 
research. This technique allows to explore and bring together the opinions of a professional group on the topic of 
interest without the difficulties and inconveniences inherent to face-to-face consensus meetings [5]. 
The method requests the individual/anonymous opinion of each panellist through a confidential online survey. The 
survey is repeated in a second round, after disseminating the group results of the first questionnaire and the written 
comments made by the panellists among the participants. This provides an opportunity for each participant to reflect 
and reconsider his/her opinion between the rounds, without the change in opinion being obvious to the rest of the 
panellists. The technique preserves anonymity, allows for controlled interaction between the group (without the risk 
of influence biases due to the presence of dominant members) and, finally, it objectively validates the consensus level 
achieved by statistical criteria. 




• 1-3: "I disagree with" (lower score implies lower degree of agreement). 
• 4-6: "I do not agree or disagree with; I do not have a fully defined opinion on the issue" (choose 4 or 6 if 
you are closer to disagreeing or agreeing, respectively). 
• 7-9: "I agree with" (higher score implies higher degree of agreement). 
After each round, the group's opinion and the consensus reached on each issue raised was determined by the position 
of the group's median score and the "level of agreement" reached by the respondents, according to the following 
criteria: 
▪ Consensus is considered to be reached regarding an item when there is "agreement" of panel opinion on the 
panel: that is, when less than one third of the respondent experts score outside the three-point region (1-3), 
(4-6), (7-9) which contains the median. In this case, the median value determines the group consensus 
reached: "majority" disagreement" with the item, if the median is ≤3, or majority "agreement" with the item 
if the median is ≥7. The cases in which the median falls within the 4-6 region will be considered "uncertain" 
items. 
▪ Conversely, it is established that exists panel opinion differences in the panel opinion when the scores of one 
third or more of the panellists are in the (1-3) region and another third or more are in the (7-9) region. The 
remaining items without agreement or disagreement is observed will be considered to have an 
"undetermined". 
All items without a clear consensus (uncertain items, those with disagreement and those “undetermined”) are proposed 
for reconsideration in the second round. Items with a high dispersion of opinion (interquartile range ≥4 points; range 
of scores contained between the p25 and p75 values of the distribution), are also re-evaluated.  
Between the rounds, the panellists were informed of response distribution in the first survey (bar charts) and comments 
and clarifications provided by each participant. After reviewing this information, they were asked to give a new 
opinion on the items not agreed in the first round.  
In addition, the second round also entailed a prioritisation scale aimed at assigning an order of priority among the 
various indicators in each block (structure, process and outcome). 
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Phase 4. Express formulation of a standardised version of the indicators selected according to SECA´s conventional 
technical format (Table 1). Setting out for each indicator: quality criterion, indicator statement, definition and 
clarifications of terms, formula for calculating the indicator, indicator type (structure, process, outcome), justification, 
calculation period, compliance level (standard/acceptable), information source for measurement, and bibliography. 
The university technical group and SECA experts developed a proposal for each item, which was submitted for 
approval to the SEOR WG. The definition of standards for each indicator (the appropriate compliance benchmarks) 
was based on available information from the literature consulted. Where such information was not available, the WG 
determined the values by consensus.  
 
RESULTS  
In the first Delphi round regarding the 28 possible indicators evaluated (from the process described in the section of 
methods), the usefulness of 23 indicators was established by consensus. No indicators were rejected. In the second 
round, the 5 indicators not previously agreed upon were revaluated and three reached agreement. Two indicators were 
eliminated due to insufficient agreement (not due to unanimous rejection by the group). Therefore, the expert panel 
validated 26 of the 28 indicators analyzed (93% of the initial proposal) (Figure 1). 
Table 1 contains the 28 indicators with their detailed results at the end of both rounds. The tables 2 and 3 show the 
indicators with their justification and the formula to follow-up, respectively. 
 
DISCUSSION  
With this project, we have established the indicators that could best measure the decision, preparation and treatment 
process in RO. For this purpose we have followed the framework used in the “Patterns of Care” in RO, developed 
between the years 1994-1997 by Hanks [6], for prostate, breast and cervical cancer in the US to evaluate the quality 
of treatments among different populations. One of the objectives of this “Patterns of Care” was the model of 
Donabedian (1988), which classified quality indicators in clinical practice [4] into three categories: structure, 
processes and outcomes.  
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Structure indicators analyze the set-up characteristics where patient care is provided, which includes material, human 
and organisational resources. Therefore, in this section we chose as indicators the number of patients treated per 
radiation oncologist and per treatment unit, distinguishing between the treatment complexity and type used (external 
beam radiotherapy; brachytherapy), common in most quality indicator studies. This is primarily based on surgical data 
that showed better results in hospitals with larger volumes of patients [7]. The treatment equipment quality and their 
obsolescence may have an impact on its operation; therefore we also introduced the quantification of interruptions due 
to breakdowns and patient referrals that may be due to equipment shortages. From the point of view of the 
organization, we believe that joint decision-making regarding treatments in tumour committees guarantees a better 
therapeutic choice and, therefore, knowing the percentage of patients evaluated in them must be taken into account. 
Finally, RO departments are not available in all hospitals, which sometimes make the access difficult, delay the 
treatment initiation and determine their end result. Thus, it was important to assess the accessibility of the service. 
Most of these structure indicators have been considered by different authors and societies and are considered for 
accreditation programmes. The advantage of these indicators is that they are usually easy to gather, given that there 
are recommendations on their values ranges. This is a controversial point, because the available ranges are very wide 
and so it is vitally important to know the real values of Spanish RO departments, which can better set the quality of 
these indicators. As Hayman says [8], although structural characteristics are important to provide good care, they do 
not guarantee quality per se, and so the relationship between structural performance and quality is more implied than 
proven.  
Process indicators measure what is actually done, the activities realized by professionals to decide upon, prepare and 
administer a treatment, thus showing the internal working of the organisation to manage their work in a consistent 
manner. Process indicators are often based on clinical trial data and are primarily focused on what we do and how we 
do it, and allow us to take swift action for improvement. Given the influence that processes have on the final service 
quality and that they are often considered the best quality measures [9], this is where we observed the most impact, 
having defined 15, with which we believe we are covering most of the RO department facets. Using them, our aim is 
to assess their capacity to respond to treatment demands with indicators such as the department response time and the 
time required for the treatment preparation process. We also pretend to assess the knowledge and equipment in order 
to apply it, using indicators such as the appropriate dose of external beam radiotherapy or brachytherapy in prostate 
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cancer, patients with head and neck tumours treated with intensity modulation, patients receiving fractionated 
extracranial stereotactic radiotherapy, the percentage of verifications performed throughout the treatment, patients 
with rectal cancer receiving neoadjuvant radiotherapy or retreated patients and re-irradiated patients. The treatment 
duration is a factor that affects the equipment workloads and the QoL of patients and their loved ones and, therefore, 
we believe the use of hypofractionated treatment regimens in prostate and breast cancer should be evaluated. Finally, 
malfunctions in established work processes can also lead to increased workloads and so we wanted to measure patients 
who require rescheduling, not due to tumour changes during treatment, and also those patients who receive treatment 
for longer than planned.  
Outcome indicators measure the effect of the care received by patients on their health and their satisfaction level. 
Thus, we place considerable value on the complications rate and patient satisfaction. In addition, we have included 
three other indicators that may indirectly influence the results: the medical records quality, reflecting the essential data 
to decide upon a treatment; the publications of the department, due to their impact on the analysis of the patients being 
treated; and the number of patients in prospective clinical studies due to what is set out in the regulations required by 
trials.  
We are aware that outcome indicators are usually focused on analysing the final effect of the treatment (survival, 
disease control); however, at least in the first phase, we have not considered them because of difficulty in collecting 
them, the time required to be significant, in case of survival 5-10 years, and the complexity due to the final outcomes 
in most tumours depend on multiple factors external to the RO departments, such as diagnosis delays, unsuitable 
surgery, improper instructions prior to radiotherapy, etc. Nevertheless, we have considered others which may lead to 
improvement measures in our preparation and treatment processes. 
The care burden of RO services often makes it difficult to collect data for the indicators we have defined, but 
fortunately our services now have more and more electronic systems that were initially designed exclusively to reduce 
the risk of errors and control the operation of linear accelerators. These systems were later extended to connect the 
scheduling and treatment systems and eventually expanded to electronic systems that store demographic, staging, 
prescription and treatment data.  
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With the support of these information systems, we must collect data prospectively to have quality indicators in a fast 
and simple way. Most data used to obtain the indicators can be easily extracted from the information systems available 
to most RO departments, even if in some cases it is necessary to make some modifications.  
In summary, we completely agree with Hayman statement [8] “I believe assessment of the quality of the care we 
deliver is central to improving the care that we provide to our patients and is an area in which we as radiation 
oncologists should assume a leadership role”. 
The Delphi method seemed to us to be the most appropriate due to providing a better intersubjective/prospective 
understanding of the difficult subject that is quality indicators in RO. In addition, it allows us to analyze preferences 
among the participants and to discuss the need for each of the indicators, as they are ultimately the ones who are going 
to use them. Finally, it allows us to create a current of opinion regarding the need to measure the quality of daily 
clinical practice and RO departments. 
Study limitations. Some of the reference quality indicator comes from data of authors environment, due to the lack 
of published data; therefore this data may not be corroborated by other Spanish departments and is, consequently, 
exposed to future modifications throughout the different phases of this project. 
Conclusions. This is the first SEOR project to measure the quality of RO departments using objective quality 
indicators. These indicators are a starting point for assessing our current situation and setting collective and individual 
improvement objectives. There is significant consensus among participants regarding which indicators can best 
measure quality in RO. These indicators can be used to classify services not only by the number of patients and 
equipment they have installed, but also by the complexity of the techniques they use, their participation in research 
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